EDIT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Editas Medicine Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.60 USD
-12.8% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 1.3% above the Trend Line and sits at 32.7% of its 52-week range. The latest completed week returned -12.8%, after a -8.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bearish with 45/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 32 out of 100
Latest Close 2.60 USD 24 Jul 2026
1W Return -12.8% latest completed week
4W Return -8.8% short-term follow-through
12W Return -10.3% quarterly tape
Trend Breadth 53.8% 28 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 11-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.97% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -12.8% Latest completed week; four-week move -8.8%. Indicator stack 68/44 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.97% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Bearish 45/100 conviction; expected move 22.1%. News sentiment 50/100 64 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 1.3% above the Trend Line and sits at 32.7% of its 52-week range. The latest completed week returned -12.8%, after a -8.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.6612-week average 0.62

12-week confirmation

Trend active11/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.66Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.8% over four weeks, -10.3% over 12 weeks, and -17.5% over one year. The current trend has remained active for 11 consecutive weeks.

Performance by holding period

1W-12.8%
4W-8.8%
12W-10.3%
26W20.4%
52W-17.5%
Active trend streak11 weeks
Active weeks in one year28
Trend breadth53.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.02Latest activity-pressure read.
Pressure change-78.3%Four-week change in activity pressure.
Leadership-10.83Latest relative-leadership reading.
RS change-67.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value11/100Relative valuation strength. Underlying universe rank 90; rank 1 is best.
Quality5/100Profitability and accounting quality. Underlying universe rank 96; rank 1 is best.
Momentum18/100Medium-term price momentum. Underlying universe rank 83; rank 1 is best.
Growth67/100Revenue and earnings growth. Underlying universe rank 34; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
10.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-40.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
5.8%
Gross profit retained from each unit of revenue.
Operating margin
-268.6%
Operating profit retained from revenue.
Free-cash-flow margin
-361.6%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
8.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-10.4%
Net share repurchases relative to market value.
Shareholder yield
-10.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBearish

EDIT shows bearish options pressure with a 45/100 conviction score, put-call volume ratio of 4.04, expected move of 22.1%, and Sharemaestro trend signal active.

Conviction45/100
Expected move22.1%
Put/call volume4.04
Pressure-51
Speculation3
Volatility96
Trend agreement50
Open options detail
Insider activity5 / 3

5 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment50/100

Weighted news tone is neutral across 64 relevant articles.

7 positive · 46 neutral · 11 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move22.1%Nearest-chain priced movement where available.
52-week drawdown-42.7%Distance below the 52-week high.
13-week volatility14.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+28.1%Week of 3 Jul.
Worst week-21.7%Week of 5 Jun.
Latest week-12.8%Week of 24 Jul.

Shape of recent returns

Strong gains11
Modest gains1
Flat weeks0
Modest losses2
Sharp losses12
Recent vol14.5%13-week weekly-return volatility.
Base vol13.1%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew12.1% / -8.8%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape36/100

Trend, activity pressure, participation, and risk combine to a 36/100 tape read.

 Indicator analysis71/100

Latest 12-week confirmation: trend 11/12, activity pressure 12/12, relative leadership 4/12.

Activity pressure 0.66; No reversal markers Next-Week ExpectancyNegative 43.97%

Next-week expectancy is negative with a 43.97% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors7/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 86; Small Cap Core rank 92 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options42/100

EDIT shows bearish options pressure with a 45/100 conviction score, put-call volume ratio of 4.04, expected move of 22.1%, and Sharemaestro trend signal active.

Bearish · Put-side pressure · Expected move 22.1% Sentiment50/100

Weighted news tone is neutral across 64 relevant articles.

EDIT|Editas Medicine Inc|Price:2.680|Chg%:+0.080 Insiders5 / 3

5 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.60 USD-12.8%2.57 USD4.17 USD0.02-10.836.5MOn
17 Jul 20262.98 USD-8.6%2.55 USD4.21 USD0.27-0.238.6MOn
10 Jul 20263.26 USD-10.7%2.53 USD4.25 USD0.314.3015.3MOn
3 Jul 20263.65 USD28.1%2.51 USD4.28 USD0.1818.5212.1MOn
26 Jun 20262.85 USD5.9%2.46 USD4.31 USD0.11-6.4617.9MOn
19 Jun 20262.69 USD7.6%2.45 USD4.35 USD0.41-15.7411.2MOn
12 Jun 20262.50 USD-7.7%2.44 USD4.38 USD0.51-19.819.0MOn
5 Jun 20262.71 USD-21.7%2.44 USD4.42 USD0.62-11.1815.1MOn
29 May 20263.46 USD25.4%2.44 USD4.47 USD0.728.4035.5MOn
22 May 20262.76 USD5.3%2.42 USD4.51 USD0.52-10.485.6MOn
15 May 20262.62 USD-15.8%2.46 USD4.55 USD0.63-13.695.5MOn
8 May 20263.11 USD7.2%2.49 USD4.59 USD0.892.496.1MOff
1 May 20262.90 USD-0.3%2.51 USD4.63 USD0.941.466.3MOff
24 Apr 20262.91 USD-16.6%2.55 USD4.68 USD0.963.827.2MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.